Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014546 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01014546 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT01014546, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic acid together with ascorbic acid may kill more cancer cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Arsenic Trioxide
- DIETARY_SUPPLEMENT Ascorbic Acid
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-04 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014546
The ClinicalTrials.gov registry entry for NCT01014546 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01014546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014546 about?
NCT01014546 is a clinical study titled "Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis". This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stoppi...
What is the current status of trial NCT01014546?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-04. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01014546?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Arsenic Trioxide (DRUG), Ascorbic Acid (DIETARY_SUPPLEMENT), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01014546?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.